Clovis price target raised to $100 from $87 at Piper Jaffray Piper Jaffray raised its price target for Clovis shares to $100 saying the company's clinical development programs are progressing well, with strong enrollment indicated for rociletinib and rucaparib trials. Piper reiterates an Overweight rating on the stock.
The stock has sold of from 90+ to 36 yesterday. Looks like it might be a good time to get into it?
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.